Welcome to our dedicated page for EYES news (Ticker: EYES), a resource for investors and traders seeking the latest updates and insights on EYES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EYES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EYES's position in the market.
Vivani Medical, Inc. (NASDAQ: VANI) has announced its trading debut on The Nasdaq Capital Market today following its merger with Nano Precision Medical, Inc. The company holds approximately $55 million in cash, aimed at advancing its product portfolio which includes the NPM-119 (exenatide implant) for Type 2 diabetes. Vivani’s focus is on developing drug and device implants for chronic diseases and visual prostheses for blindness. CEO Adam Mendelsohn expressed optimism about the future of the company and its technologies, particularly the NanoPortal implant technology.
Second Sight Medical Products, Inc. has successfully merged with Nano Precision Medical, Inc., now rebranded as Vivani Medical, Inc., trading under the ticker VANI on Nasdaq. Following the merger, Vivani has approximately
Second Sight Medical Products, Inc. (NASDAQ: EYES) held its annual meeting on
Second Sight Medical Products (NASDAQ: EYES) announced the release of $1.1 million in year four funding from the NIH for its Early Feasibility Clinical Trial of the Orion Visual Cortical Prosthesis. This funding is part of a larger $6.4 million grant aimed at supporting the Orion Trial at UCLA and Baylor College of Medicine. Orion aims to provide artificial vision to those blinded by various conditions. No peer-reviewed data is currently available, and the trial is ongoing.
Second Sight Medical Products, Inc. (NASDAQ: EYES) announces an upcoming interview with CEO Adam Mendelsohn of Nano Precision Medical, Inc. (NPM), airing on The RedChip Money Report® on April 16 at 7 p.m. ET. The interview will discuss the recent announcement of a merger between Second Sight and NPM in an all-stock transaction, allowing NPM to become a wholly-owned subsidiary. This merger aims to develop innovative medical implants for chronic diseases. Second Sight focuses on neuromodulation devices for blindness, enhancing visual prosthetics for patients.
Second Sight Medical Products (EYES) has announced a definitive agreement to acquire Nano Precision Medical (NPM) in an all-stock transaction. The merger will result in Second Sight shareholders owning approximately 23% of the combined company, which aims to leverage NPM's innovative drug implant technology for chronic disease treatment. NPM's lead program, NPM-119, targets Type 2 diabetes, and the merger is expected to complete in Q2/Q3 2022. Second Sight currently holds over $69M for advancements in both NPM's clinical trials and visual prosthesis opportunities.
Second Sight Medical Products, Inc. (NASDAQ: EYES) announced a grant supplement of $155,964 from the NIH for a qualitative study on the perceptions of risks and benefits regarding visual neuroprostheses by profoundly blind individuals. This study is linked to a $6.4 million NIH grant for the Early Feasibility Clinical Trial of the Orion Visual Cortical Prosthesis. Orion aims to provide artificial vision to blind individuals through a device that converts images into electrical pulses sent to the brain's visual cortex. Current studies are being conducted at UCLA and the Baylor College of Medicine.
Second Sight Medical Products, Inc. (NASDAQ: EYES) has successfully closed an underwritten public offering of 11,500,000 shares at $5.00 per share, raising gross proceeds of $57,500,000. The funds will primarily support the development of the Orion device, an implant intended to restore useful vision for blind individuals by converting images into electrical pulses sent to the brain. The offering was managed by ThinkEquity and conducted under a previously declared shelf registration with the SEC.
Second Sight Medical Products, Inc. (NASDAQ: EYES) announced a public offering of 10,000,000 shares at $5.00 each, aiming for $50 million in gross proceeds. The offering, expected to close on June 25, 2021, includes a 45-day option for underwriters to buy an additional 1,500,000 shares. Proceeds will primarily support the development of the Orion visual prosthesis system. The company has previously filed a registration statement with the SEC, and the offering is managed by ThinkEquity.
Second Sight Medical Products (NASDAQ: EYES) announced a public offering of its common stock, with all shares being sold by the Company. The offering is contingent on market conditions, with no guarantee regarding its size or completion. Proceeds will mainly support the development of the Orion device, a visual prosthetic aimed at providing artificial vision to blind individuals. ThinkEquity is acting as the sole book-running manager. The offering will utilize a shelf registration statement previously filed with the SEC.
